Medscape

GIST Recurrence Risk Underestimated 'in a Third of Patients'

Physicians are underestimating the risk for recurrence in more than a third of patients who have undergone resection of a gastrointestinal stromal tumor (GIST). The result is that many patients do not ...
Cure Today

Gleevec Interruption in GIST Associated with Resistance, Recurrence, Death

Continuous Gleevec treatment in GIST patients significantly prolongs progression-free survival and delays resistance compared to treatment interruption. Median progression-free survival was 6.1 months ...
ascopubs.org

Personalized tumor-informed circulating tumor DNA analysis in monitoring recurrence following resection of high-risk stage II-III gastrointestinal stromal tumor.

Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors ...
Medscape

Long-Term Imatinib Extends Survival in High-Risk GIST

June 6, 2011 (Chicago, Illinois) — Extended adjuvant treatment with imatinib (Gleevec) improves survival in patients with high-risk gastrointestinal stromal tumors (GIST). Imatinib administered for 3 ...
Cure Today

Why Is Specialized Care Important For GIST Treatment?

Treatment for GIST depends on tumor size, location, and genetic mutations, with options including observation, surgery, and targeted therapies. Expert consultation and multidisciplinary input are ...
ascopubs.org

Personalized tumor-informed circulating tumor DNA analysis in monitoring recurrence following resection of high-risk locally advanced stage gastrointestinal stromal tumor.

The benefit of cytoreductive surgery during imatinib (IM) therapy in patients with metastatic gastrointestinal stromal tumors (mGISTs): Retrospective analysis from several cancer centers.